Transaction details
Baskett Forest, identified as a ten percent owner of Korro Bio, Inc. (NASDAQ: KRRO), executed a purchase on March 10, 2026, acquiring 207,100 shares of Korro Bio common stock at $11.11 per share. The purchase of those common shares amounted to $2,300,881. In the same transaction, Baskett Forest also obtained 242,945 Pre-Funded Warrants at a price of $11.109 each. After the close of this transaction, Baskett Forest indirectly holds 1,297,893 shares of Korro Bio.
Market context and timing
The transaction occurred while Korro Bio's shares were trading near $11.50. Over the past six months, the company's stock has fallen 62.61%, despite staging a 43.57% recovery so far year-to-date. The timing of the acquisition is notable: Korro Bio is scheduled to report earnings on March 18, 2026, five calendar days after the March 10 transaction.
Balance sheet and analyst outlook
According to InvestingPro, Korro Bio's balance sheet shows more cash than debt. However, analysts do not expect the company to reach profitability during the current year, based on the same InvestingPro data.
Corporate financing and investor interest
In a separate corporate development, Korro Bio announced an $85 million private investment in public equity (PIPE) financing. The financing round was led by Venrock Healthcare Capital Partners, with participation from investors including ADAR1 Capital Management and New Enterprise Associates.
Analyst rating changes
Several brokerages have upgraded Korro Bio in recent coverage. Clear Street raised its rating to Buy from Hold and set a price target of $18.00, citing the potential of the KRRO-121 program for hyperammonemia. H.C. Wainwright upgraded Korro Bio to Buy with a $20.00 target, highlighting the potential of a new liver-targeted RNA editing drug. Piper Sandler moved the stock to Overweight and increased its price target to $30.00 following the introduction of KRRO-121 for Urea Cycle Disorders and Hepatic Encephalopathy. These analyst actions reflect growing attention to the company’s drug development programs.
Summary and implications
The insider purchase by an existing large shareholder, the concurrent pre-funded warrant acquisition, an $85 million PIPE led by Venrock Healthcare Capital Partners, and multiple analyst upgrades together form a cluster of developments occurring ahead of Korro Bio’s earnings release. The company’s cash position relative to debt is noted by InvestingPro, though profitability this year is not anticipated by analysts.
Key considerations
- Insider activity - a substantial purchase by a 10% owner increases that holder’s indirect stake to 1,297,893 shares.
- Financing - the $85 million PIPE led by Venrock Healthcare Capital Partners and participation from ADAR1 Capital Management and New Enterprise Associates.
- Analyst sentiment - multiple upgrades and higher price targets tied to KRRO-121 and liver-targeted RNA editing programs.
Risks and uncertainties
- Near-term volatility - the purchase occurred five days before the company’s March 18 earnings announcement, a period that may increase price movement.
- Profitability outlook - analysts do not expect Korro Bio to be profitable this year despite its cash position, per InvestingPro.
- Market performance - the stock has declined 62.61% over six months, even with a 43.57% year-to-date recovery, indicating persistent downside risk.